Patients with relapsed T-cell acute lymphoblastic leukemia (T-ALL) once faced a median survival prognosis of six months after relapse. Clinical trials of WU-CART-007, a new CRISPR-engineered cell therapy, now show an overall response rate of 91 percent and a complete remission rate of 72.7 percent. It is the first CAR-T cell product designed specifically to work against T-cell cancers.
A Therapeutic Gap, Decades in the Making
CAR-T cell therapies fundamentally changed the treatment of certain blood cancers from 2017 onward. In this approach, immune cells are taken from a patient, genetically modified to recognize and attack cancer cells, and then reinfused. For B-cell lymphomas and B-cell leukemias, the procedure is now standard therapy for relapses.
For T-cell cancers, the same approach kept failing. The biological problem: T-cell cancer cells and normal T cells carry the same surface marker, the protein CD7. When CAR-T cells are given this marker as a target, they destroy not just cancer cells but also the engineered immune cells themselves, a phenomenon called fratricide. This made T-cell-directed CAR-T therapies impractical for years.
T-ALL disproportionately affects children and young adults. After relapse following chemotherapy or stem cell transplantation, there was no approved, potentially curative option.
CRISPR Solves the Fratricide Problem
Biotech company Wugen, founded from Washington University School of Medicine in St. Louis, solved the problem using the CRISPR/Cas9 gene-editing tool. Their product WU-CART-007, known generically as soficabtagene geleucel, uses CRISPR to delete two genes from the therapeutic immune cells.
First, the CD7 gene is removed. The CAR-T cells no longer carry the marker themselves and cannot be recognized as a target. Second, CRISPR removes the TRAC gene, which encodes the T-cell receptor. Without this receptor, the risk of graft-versus-host disease drops significantly, a condition where transplanted immune cells attack the recipient's body.
The result: modified immune cells survive, find cancer cells via the CD7 marker, and eliminate them. In a Phase 1/2 clinical trial published in the Journal of Clinical Oncology, 91 percent of evaluable patients responded to treatment. 72.7 percent achieved complete remission, meaning the full disappearance of all measurable signs of disease.
Off-the-Shelf: No Waiting Time
A practical advantage over conventional CAR-T therapies concerns manufacturing. Standard CAR-T products are made individually from each patient's own immune cells. This takes weeks and often costs several hundred thousand dollars. Patients with aggressive relapse frequently do not have that time.
WU-CART-007 is allogeneic: it is made from healthy donor immune cells and stockpiled in advance. The product can be deployed immediately when needed, similar to a blood transfusion. Wugen secured $115 million in early 2026 for an ongoing global pivotal trial to confirm these advantages in a larger patient group.
FDA Status and Outlook
In January 2026, the U.S. Food and Drug Administration granted WU-CART-007 Breakthrough Therapy Designation, signaling that the FDA views the treatment as potentially significant over existing therapies and will work closely with the developer to accelerate development. The product also holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations.
Wugen plans to submit a Biologics License Application in 2027. A favorable pivotal trial could lead to the first U.S. approval by 2028, after which a separate review by the European Medicines Agency would follow.
One significant limitation remains: all efficacy data so far come from an early-phase trial without a randomized control group. Whether the high response rate holds up in direct comparison to other therapies will be confirmed in the ongoing pivotal study. The median follow-up time in the Phase 1/2 trial was still short, leaving long-term remission rates unknown.